Hormonal
Endogenous peripheral GLP-1 enhances glucose-induced insulin release primarily through a vago-vagal reflex mediated by GLP-1 receptors on vagal sensory fibers, rather than through direct endocrine action on pancreatic beta-cells.
Your body's natural response to eating involves a complex gut-brain-heart axis. GLP-1 released from your gut doesn't just float to your pancreas; it signals your vagus nerve to help manage insulin. This highlights the importance of the neural connection between digestion and metabolic control, suggesting that factors affecting nerve health or gut signaling might influence metabolic efficiency.
a substantial part of the GLP-1 effect on glucose-induced insulin release appears to be mediated by a vago-vagal reflex... GLP-1Rs on vagal sensory fibers terminating in the wall of the hepatic portal vein are involved in mediating the effect of endogenous intestinal GLP-1 on insulin secretion and glucose tolerance
Why this rating
Based on receptor knockdown and antagonist studies in rodents showing attenuation of insulin response.
Source
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Jean‐Philippe Krieger et al. · Comprehensive physiology · 2024
DOI 10.1002/cph4.7
More from this paper
- Central GLP-1 produced by hindbrain PPG neurons and peripheral GLP-1 from intestinal L-cells regulate food intake through independent pathways, rather than acting synergistically or additively.Good
- Intestinal GLP-1 from colonic L-cells is likely not involved in the acute control of meal size or thirst, but may play a role in long-term fluid balance and cardiovascular function.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →